Center for Biomolecular Magnetic Resonance (BMRZ), Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Max-von-Laue-Straße 7, 60438, Frankfurt am Main, Germany.
Chair of Proteomics and Bioanalytics, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354, Freising, Germany.
ChemMedChem. 2018 Aug 20;13(16):1629-1633. doi: 10.1002/cmdc.201800398. Epub 2018 Jul 20.
Erythropoietin-producing hepatocellular (EPH) receptors are transmembrane receptor tyrosine kinases. Their extracellular domains bind specifically to ephrin A/B ligands, and this binding modulates intracellular kinase activity. EPHs are key players in bidirectional intercellular signaling, controlling cell morphology, adhesion, and migration. They are increasingly recognized as cancer drug targets. We analyzed the binding of NVP-BHG712 (NVP) to EPHA2 and EPHB4. Unexpectedly, all tested commercially available NVP samples turned out to be a regioisomer (NVPiso) of the inhibitor, initially described in a Novartis patent application. They only differ by the localization of a single methyl group on either one of two adjacent nitrogen atoms. The two compounds of identical mass revealed different binding modes. Furthermore, both in vitro and in vivo experiments showed that the isomers differ in their kinase affinity and selectivity.
促红细胞生成素产生肝细胞 (EPH) 受体是跨膜受体酪氨酸激酶。它们的细胞外结构域特异性结合到 Ephrin A/B 配体,这种结合调节细胞内激酶活性。EPH 是双向细胞间信号传递的关键参与者,控制细胞形态、黏附和迁移。它们越来越被认为是癌症药物靶点。我们分析了 NVP-BHG712 (NVP) 与 EPHA2 和 EPHB4 的结合。出乎意料的是,所有测试的市售 NVP 样品都是抑制剂的立体异构体 (NVPiso),最初在诺华的一份专利申请中描述。它们仅在两个相邻氮原子之一上的单个甲基的定位上有所不同。两种具有相同质量的化合物显示出不同的结合模式。此外,体外和体内实验均表明,两种异构体在激酶亲和力和选择性上存在差异。